Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) PT at $31.67

Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) have earned a consensus rating of “Buy” from the seven ratings firms that are currently covering the firm, MarketBeat reports. Seven research analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have issued a report on […]

Leave a Reply

Your email address will not be published.

Previous post Reviewing HUYA (NYSE:HUYA) & Nexxen International (NASDAQ:NEXN)
Next post Contrasting Wynn Macau (OTCMKTS:WYNMY) and Civeo (NYSE:CVEO)